Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp443 | Osteoporosis: treatment | ECTS2013

Zoledronic acid vs alendronate in the management of osteoporosis

Ferguson Lyn , Panarelli Maurizio , Dargie Rosemary

Zoledronic acid has been shown to reduce the risk of fractures and improve bone mineral density (BMD) in osteoporosis vs placebo. This study compared changes in BMD in patients with osteoporosis treated with zoledronic acid vs alendronate. BMD at the lumbar spine and total hip pre- and post-bisphosphonate were recorded for 65 patients with osteoporosis (T score ≤−2.5) from retrospective analysis of DEXA scans. 35 patients received annual 5 mg IV zoledronic...